Central retinal vein occlusion as a possible presenting manifestation of Sneddon syndrome.
Aggermann
Tina
T
Haas
Paulina
P
Binder
Susanne
S
D017985:Dalteparin / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005654:Fundus Oculi; D006801:Humans; D054068:Livedo Reticularis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D012164:Retinal Diseases / Q000175:diagnosis* / Q000209:etiology* / Q000503:physiopathology; D012169:Retinal Vein / Q000473:pathology / Q000503:physiopathology; D012170:Retinal Vein Occlusion / Q000175:diagnosis* / Q000209:etiology* / Q000503:physiopathology; D018860:Sneddon Syndrome / Q000150:complications*; D016896:Treatment Outcome; D015354:Vision, Low / Q000209:etiology*
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D017985:Dalteparin; D010431:Pentoxifylline